Overview

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Status:
Approved for marketing

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to expand upon the safety data for carfilzomib by providing expanded access to patients with relapsed and refractory multiple myeloma who are unable to enroll in any other ongoing carfilzomib trial.

Details

Lead Sponsor:

Amgen
Onyx Pharmaceuticals

Collaborator:

Multiple Myeloma Research Foundation